Table 3.

ORs and 95% CIs for the association between metabolic syndrome and endometrial cancer subtype, SEER–Medicare

Endometrioid grade 1–2 (n = 5,516)Endometrioid grade 3 (n = 1,478)Adenocarcinoma (n = 5,219)
n (%)ORa (95% CI)n (%)ORa (95% CI)n (%)ORa (95% CI)
Metabolic conditions
 Overweight/obesity435 (7.9)2.08 (1.86–2.34)106 (7.2)1.93 (1.56–2.38)277 (5.3)1.89 (1.64–2.17)
 Impaired fasting glucose1,551 (28.1)1.36 (1.27–1.46)400 (27.1)1.28 (1.14–1.45)1,160 (22.2)1.33 (1.24–1.44)
 High blood pressure3,877 (70.3)1.33 (1.25–1.42)1,055 (71.4)1.37 (1.22–1.55)3,349 (64.2)1.40 (1.31–1.50)
 High triglycerides2,431 (44.1)1.20 (1.13–1.28)608 (41.1)1.11 (0.99–1.24)1,558 (29.9)1.22 (1.14–1.31)
Metabolic syndromeb
 NCEP-III987 (17.9)1.42 (1.31–1.53)260 (17.6)1.40 (1.21–1.61)561 (10.8)1.41 (1.27–1.56)
 IDF303 (5.5)2.09 (1.83–2.40)73 (4.9)2.02 (1.57–2.59)165 (3.2)1.99 (1.67–2.38)
Serous (n = 1,111)Clear cell (n = 291)Mucinous (n = 206)
n (%)ORa (95% CI)n (%)ORa (95% CI)n (%)ORa (95% CI)
Metabolic conditions
 Overweight/obesity76 (6.8)1.85 (1.45–2.36)17 (5.8)1.68 (1.01–2.77)17 (8.3)2.71 (1.63–4.49)
 Impaired fasting glucose336 (30.2)1.45 (1.27–1.67)86 (29.6)1.39 (1.07–1.81)48 (23.3)1.21 (0.87–1.69)
 High blood pressure744 (67.0)1.12c (0.98–1.28)210 (72.2)1.42 (1.09–1.85)149 (72.3)1.74 (1.27–2.38)
 High triglycerides439 (39.5)1.19 (1.05–1.36)104 (35.7)1.06 (0.82–1.38)80 (38.8)1.42 (1.05–1.92)
Metabolic syndromeb
 NCEP-III192 (17.3)1.41 (1.19–1.67)50 (17.2)1.46 (1.06–2.02)33 (16.0)1.69 (1.14–2.50)
 IDF61 (5.5)2.29 (1.74–3.01)13 (4.5)2.03 (1.15–3.60)15 (7.3)4.06c (2.36–6.99)
Carcinosarcoma (n = 912)Sarcoma (n = 237)Other (n = 816)
n (%)ORa (95% CI)n (%)ORa (95% CI)n (%)ORa (95% CI)P-het
Metabolic conditions
 Overweight/obesity64 (7.0)1.87 (1.43–2.45)17 (7.2)1.89 (1.14–3.13)64 (7.8)2.07 (1.58–2.71)0.82
 Impaired fasting glucose245 (26.9)1.20 (1.03–1.40)59 (24.9)1.16 (0.85–1.57)255 (31.3)1.43 (1.23–1.67)0.35
 High blood pressure638 (70.0)1.23 (1.06–1.43)165 (69.6)1.33 (1.00–1.78)571 (70.0)1.09 (0.93–1.28)0.12
 High triglycerides311 (34.1)0.89c (0.76–1.03)84 (35.4)0.92 (0.69–1.22)322 (39.5)0.93c (0.80–1.08)< 0.01
Metabolic syndromeb
 NCEP-III137 (15.0)1.14 (0.94–1.38)39 (16.5)1.34 (0.94–1.92)151 (18.5)1.31 (1.08–1.58)0.82
 IDF37 (4.1)1.58 (1.12–2.24)13 (5.5)2.17 (1.22–3.85)49 (6.0)2.34 (1.72–3.17)0.31
  • aORs adjusted for diagnosis date, age, race/ethnicity, registry area, and tobacco use.

  • bNCEP-III: US National Cholesterol Education Program Adult Treatment Panel III defines metabolic syndrome as the presence of at least three of the following conditions: central adiposity/elevated waist circumference, hypertension, high triglycerides, low HDL cholesterol, and impaired fasting glucose; IDF: International Diabetes Foundation defines metabolic syndrome as the presence of central adiposity/elevated waist circumference plus any 2 of the other factors (impaired fasting glucose, hypertension, low HDL cholesterol, and high triglycerides).

  • cP <0.05 for pairwise comparison with low-grade (1 or 2) endometrioid-type tumors.